Francesco Patti

List of Publications by Year in descending order

331 papers	12,600 citations	33972 52 h-index	43165 92 g-index
363 all docs	363 docs citations	363 times ranked	12606 citing authors

#	Article	IF	Citations
1	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.4	526
2	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2019, 381, 2114-2124.	30.1	428
3	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.8	389
4	The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Multiple Sclerosis Journal, 2006, 12, 787-793.	3.3	352
5	The Global Adherence Project (GAP): a multicenter observational study on adherence to diseaseâ€modifying therapies in patients with relapsingâ€remitting multiple sclerosis. European Journal of Neurology, 2011, 18, 69-77.	3.6	304
6	Cognitive and psychosocial features of childhood and juvenile MS. Neurology, 2008, 70, 1891-1897.	1.1	258
7	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Multiple Sclerosis Journal, 2017, 23, 1258-1267.	3.3	230
8	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.1	229
9	Cognitive and psychosocial features in childhood and juvenile MS. Neurology, 2010, 75, 1134-1140.	1.1	202
10	Cognitive-motor dual-task interference: A systematic review of neural correlates. Neuroscience and Biobehavioral Reviews, 2017, 75, 348-360.	6.6	195
11	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€“remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788.	3.3	178
12	Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference and Adherence, 2010, 4, 1.	1.9	149
13	Pregnancy and fetal outcomes after interferon-Î² exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802.	1.1	146
14	Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology, 2005, 65, 280-285.	1.1	143
15	Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150.	1.1	137
16	Cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 2-8.	3.3	135
17	Realâ€life impact of early interferonÎ² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	5.8	134
18	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	10.4	126

#	Article	IF	Citations
19	Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 123-131.	3.3	120
20	Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. Journal of Neuroimmunology, 1996, 70, 87-90.	2.4	112
21	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	105
22	Rituximab for the treatment of multiple sclerosis: a review. Journal of Neurology, 2022, 269, 159-183.	3.8	105
23	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology, 2021, 78, 414.	9.3	103
24	Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. Journal of the Neurological Sciences, 2003, 211, 55-62.	0.6	102
25	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424.	3.3	102
26	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	6.0	95
27	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	94
28	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.1	91
29	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Journal of the Neurological Sciences, 2008, 269, 49-53.	0.6	89
30	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	1.8	84
31	CIRCULATING SERUM LEVELS OF IL-1ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN-Î² TREATMENT. Cytokine, 1996, 8, 395-400.	3.2	81
32	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	1.8	81
33	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	3.3	80
34	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Multiple Sclerosis Journal, 2007, 13, 412-419.	3.3	78
35	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	8.0	78
36	Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. Journal of Neurology, 2008, 255, 1250-1253.	3.8	74

#	Article	IF	Citations
37	Blood levels of transforming growth factor-beta 1 (TGF-Î²1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-Î²1b). Clinical and Experimental Immunology, 1998, 113, 96-99.	2.7	73
38	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	2.0	73
39	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679.	2.5	71
40	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	2.0	69
41	Headache and Multiple Sclerosis: A Population-Based Case-Control Study in Catania, Sicily. Cephalalgia, 2008, 28, 1163-1169.	4.2	66
42	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	6.0	66
43	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	5.8	62
44	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	8.0	61
45	Prevalence and incidence of multiple sclerosis in Catania, Sicily. Neurology, 2001, 56, 62-66.	1.1	60
46	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.8	60
47	COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.8	60
48	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	8.0	58
49	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	10.4	58
50	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626.	3.3	57
51	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 1029-1042.	2.8	56
52	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). Journal of the Neurological Sciences, 2013, 331, 94-97.	0.6	53
53	Subcutaneous Interferon Î²-1a May Protect against Cognitive Impairment in Patients with Relapsingâ€“Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111.	2.5	53
54	Lateâ€onset and youngâ€onset relapsingâ€remitting multiple sclerosis: evidence from a retrospective longâ€term followâ€up study. European Journal of Neurology, 2018, 25, 1425-1431.	3.6	51

#	Article	IF	Citations
55	Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 404-407.	6.0	50
56	Botulinum toxin improves dysphagia associated with multiple sclerosis. European Journal of Neurology, 2011, 18, 486-490.	3.6	50
57	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. PLoS ONE, 2016, 11, e0160261.	2.5	50
58	Early use of high-efficacy diseaseâ€'modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	3.8	50
59	Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. Journal of Neurology, 2017, 264, 494-502.	3.8	49
60	Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. International Journal of Environmental Research and Public Health, 2020, 17, 2882.	2.7	49
61	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€"remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	3.8	48
62	Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily. Journal of Neurology, 2015, 262, 923-930.	3.8	47
63	Possible increasing risk of multiple sclerosis in Catania, Sicily. Neurology, 2005, 65, 1259-1263.	1.1	46
64	Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology, 2013, 261, 82-86.	2.4	46
65	Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI. Multiple Sclerosis International, 2014, 2014, 1-9.	0.8	46
66	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	2.7	46
67	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. Journal of Neurology, 2018, 265, 828-835.	3.8	46
68	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	3.8	46
69	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114.	4.3	46
70	An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. Journal of Neurology, 2021, 268, 3249-3268.	3.8	46
71	Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€"remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgBT /Overlo	3.8	45
72	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. Journal of Neurology, 2016, 263, 1727-1735.	3.8	45

#	Article	IF	Citations
73	Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. Environmental Health, 2017, 16, 91.	4.2	45
74	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurological Sciences, 2019, 40, 1651-1657.	2.0	45
75	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	45
76	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurological Sciences, 2011, 32, 1223-1231.	2.0	44
77	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52.	1.5	44
78	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	2.0	43
79	Predictors of quality of life among patients with multiple sclerosis: An Italian cross-sectional study. Journal of the Neurological Sciences, 2007, 252, 121-129.	0.6	42
80	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517.	3.3	42
81	Cognitive assessment in multiple sclerosisâ€”an Italian consensus. Neurological Sciences, 2018, 39, 1317-1324.	2.0	42
82	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407.	3.3	41
83	Frequency and severity of headache is worsened by Interferon-Î² therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2012, 125, 91-95.	2.2	40
84	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.6	39
85	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Safety, 2016, 39, 1163-1174.	3.2	39
86	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 663-674.	3.3	39
87	Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. International Journal of Environmental Research and Public Health, 2020, 17, 857.	2.7	39
88	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.3	38
89	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.8	37
90	Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. Multiple Sclerosis Journal, 2011, 17, 273-280.	3.3	36

#	Article	IF	Citations
91	The Raoâ€™s Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. Neurological Sciences, 2014, 35, 79-82.	2.0	36
92	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple Sclerosis Journal, 2018, 24, 1234-1242.	3.3	36
93	Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Multiple Sclerosis and Related Disorders, 2019, 27, 324-326.	2.1	35
94	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. European Journal of Neurology, 2016, 23, 964-972.	3.6	34
95	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 2106-2111.	3.3	34
96	Multiple sclerosis in Italy: cost-of-illness study. Neurological Sciences, 2011, 32, 787-794.	2.0	33
97	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	33
98	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	3.3	33
99	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic Journal, 0, , .	0.3	33
100	Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. European Journal of Neurology, 1998, 5, 283-286.	3.6	32
101	Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients. Clinical Neuropharmacology, 2013, 36, 114-116.	0.7	32
102	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. Frontiers in Psychology, 2017, 8, 2216.	2.3	32
103	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.1	32
104	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS ONE, 2016, 11, e0153466.	2.5	32
105	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1355-1359.	6.0	31
106	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Multiple Sclerosis Journal, 2014, 20, 220-226.	3.3	31
107	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092268.	3.8	31
108	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.3	31

#	Article	IF	Citations
109	Risk of Getting COVID-19 in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.8	31
110	Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Journal of Neurology, 2004, 251, 1502-1506.	3.8	30
111	The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2005, 252, 1255-1261.	3.8	30
112	Determinants of Sexual Impairment in Multiple Sclerosis in Male and Female Patients with Lower Urinary Tract Dysfunction: Results from an Italian Cross-Sectional Study. Journal of Sexual Medicine, 2014, 11, 2406-2413.	0.7	30
113	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	2.0	30
114	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	1.8	30
115	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics, 2015, 15, 803-824.	2.8	30
116	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	2.0	30
117	Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated. Toxins, 2018, 10, 55.	3.5	30
118	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303.	6.0	30
119	Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurologica Scandinavica, 2006, 113, 241-247.	2.2	29
120	Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. European Journal of Neurology, 2019, 26, 41-50.	3.6	29
121	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672.	5.9	29
122	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	8.0	29
123	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174.	4.7	29
124	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184.	1.7	28
125	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1431-1442.	3.3	28
126	A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. International Journal of Molecular Sciences, 2016, 17, 1725.	4.2	28

#	Article	IF	Citations
127	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. Journal of the Neurological Sciences, 2016, 366, 139-145.	0.6	28
128	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651.	2.5	28
129	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Journal of the Neurological Sciences, 2004, 223, 69-71.	0.6	27
130	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clinical and Experimental Immunology, 2009, 159, 159-168.	2.7	27
131	Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. Journal of the Neurological Sciences, 2010, 288, 96-100.	0.6	27
132	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	3.8	27
133	Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Multiple Sclerosis and Related Disorders, 2020, 46, 102561.	2.1	27
134	Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opinion on Investigational Drugs, 2012, 21, 1679-1699.	4.0	26
135	Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. Frontiers in Neurology, 2019, 10, 337.	2.5	26
136	Treatment options of cognitive impairment in multiple sclerosis. Neurological Sciences, 2010, 31, 265-269.	2.0	25
137	Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. PLoS ONE, 2012, 7, e41227.	2.5	25
138	Restless legs syndrome and multiple sclerosis: a population based caseâ˜control study in Catania, Sicily. European Journal of Neurology, 2015, 22, 1018-1021.	3.6	25
139	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	25
140	EAN guideline on palliative care of people with severe, progressive multiple sclerosis. European Journal of Neurology, 2020, 27, 1510-1529.	3.6	25
141	Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. Multiple Sclerosis Journal, 2016, 22, 581-589.	3.3	24
142	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.6	23
143	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Multiple Sclerosis and Related Disorders, 2022, 66, 104025.	2.1	23
144	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102492.	2.1	22

#	Article	IF	Citations
145	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurological Sciences, 2013, 34, 1633-1637.	2.0	21
146	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.6	21
147	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	2.5	21
148	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	3.8	21
149	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	1.8	21
150	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	3.6	21
151	Box and block test, hand grip strength and nineâ€hole peg test: correlations between three upper limb objective measures in multiple sclerosis. European Journal of Neurology, 2020, 27, 2523-2530.	3.6	21
152	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Multiple Sclerosis and Related Disorders, 2020, 42, 102124.	2.1	21
153	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	1.5	21
154	Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	3.6	21
155	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. Journal of Neurology, 2005, 252, 921-925.	3.8	20
156	Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. European Journal of Neurology, 2015, 22, 485-492.	3.6	20
157	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Multiple Sclerosis Journal, 2018, 24, 167-174.	3.3	20
158	Management of dysphagia in multiple sclerosis: current best practice. Expert Review of Gastroenterology and Hepatology, 2019, 13, 47-54.	3.0	20
159	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	3.3	20
160	When the word doesn't come out: A synthetic overview of dysarthria. Journal of the Neurological Sciences, 2016, 369, 354-360.	0.6	19
161	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246.	1.7	19
162	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.8	19

#	Article	IF	Citations
163	Clinical features of Sjogrenâ€™s syndrome in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 124, 109-114.	2.2	18
164	Multiple sclerosis: getting personal with induced pluripotent stem cells. Cell Death and Disease, 2015, 6, e1806-e1806.	6.4	18
165	Offspring Number Does Not Influence Reaching the Disabilityâ€™s Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. International Journal of Molecular Sciences, 2016, 17, 234.	4.2	18
166	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. Journal of Neurology, 2016, 263, 1802-1809.	3.8	18
167	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 961-963.	3.3	17
168	Multiple Sclerosis in the Mount Etna Region: Possible Role of Volcanogenic Trace Elements. PLoS ONE, 2013, 8, e74259.	2.5	17
169	Expression of DNA methylation genes in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 290, 66-69.	2.4	17
170	Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients. Journal of Clinical Medicine, 2019, 8, 2022.	2.5	17
171	Comparing 16 Different Dualâ€“Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitiveâ€“Motor Interference. Frontiers in Neurology, 2020, 11, 918.	2.5	17
172	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. Environmental Research, 2020, 188, 109820.	7.7	17
173	Exploring polypharmacy phenomenon in newly diagnosed relapsingâ€“remitting multiple sclerosis: a cohort ambispective single-centre study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232098312.	2.6	17
174	Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. Multiple Sclerosis and Related Disorders, 2022, 57, 103361.	2.1	17
175	Patients with multiple sclerosis: a burden and cost of illness study. Journal of Neurology, 2022, 269, 5127-5135.	3.8	17
176	An exploration of anger phenomenology in multiple sclerosis. European Journal of Neurology, 2009, 16, 1312-1317.	3.6	16
177	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurological Sciences, 2016, 37, 613-622.	2.0	16
178	Computer-assisted cognitive rehabilitation on freezing of gait in Parkinsonâ€™s disease: A pilot study. Neuroscience Letters, 2017, 654, 38-41.	2.1	16
179	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-Î²1a using RebiSmartâ„¢â€”the FUTURE study. Neurological Sciences, 2017, 38, 1999-2005.	2.0	16
180	An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 2249-2263.	1.9	16

#	Article	IF	Citations
181	An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2019, 18, 925-948.	2.5	15
182	Toxoplasma gondii and multiple sclerosis: a population-based caseâ€“control study. Scientific Reports, 2020, 10, 18855.	3.4	15
183	EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. Journal of Palliative Medicine, 2020, 23, 1426-1443.	1.2	15
184	Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurological Sciences, 2020, 41, 2905-2913.	2.0	15
185	Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Multiple Sclerosis Journal, 2023, 29, 221-235.	3.3	15
186	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
187	Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
188	Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. Neurological Sciences, 2020, 41, 1075-1079.	2.0	14
189	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.3	14
190	Risk factors in multiple sclerosis: a population-based caseâ€“control study in Sicily. Background and methods. Neurological Sciences, 2016, 37, 1931-1937.	2.0	13
191	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866.	3.3	13
192	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.3	13
193	Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter doubleâ€blind, placeboâ€controlled, crossover study. European Journal of Neurology, 2020, 27, 2209-2216.	3.6	13
194	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	2.3	13
195	Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction. International Neurourology Journal, 2015, 19, 272-277.	1.3	13
196	Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. Functional Neurology, 2016, 31, 21-3.	2.2	13
197	A realâ€world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described â€˜spasticityâ€plus syndromeâ€™. European Journal of Neurology, 2022, 29, 2744-2753.	3.6	13
198	Italian Validation of the 12-Item Multiple Sclerosis Walking Scale. Multiple Sclerosis International, 2015, 2015, 1-6.	0.8	12

#	Article	IF	Citations
199	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391.	2.0	12
200	Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. Neurological Sciences, 2021, 42, 2837-2845.	2.0	12
201	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944.	3.8	12
202	Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurology, 2021, 21, 324.	1.8	12
203	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.6	12
204	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon Î²-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125.	1.8	11
205	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811.	3.3	11
206	Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 583-589.	2.2	11
207	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. Environmental Research, 2020, 182, 109022.	7.7	11
208	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. Expert Opinion on Pharmacotherapy, 2020, 21, 1449-1454.	1.9	11
209	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103385.	2.1	11
210	Management of swallowing disorders in multiple sclerosis. Neurological Sciences, 2006, 27, s338-s340.	2.0	10
211	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. Quality of Life Research, 2016, 25, 2755-2763.	3.2	10
212	Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis. Neurological Sciences, 2020, 41, 1539-1546.	2.0	10
213	The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. Dysphagia, 2021, 36, 192-197.	2.1	10
214	Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. Neurological Sciences, 2022, 43, 1903-1910.	2.0	10
215	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurology and Therapy, 2021, 10, 627-649.	3.5	10
216	Immunological Subsets Characterization in Newly Diagnosed Relapsingâ€“Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 819136.	4.9	10

#	Article	IF	Citations
217	Longitudinal changes in social functioning in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon Î²-1a: results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgBT/Overlock	4.2	9
218	Interferon-beta-1a treatment has a positive effect on quality of life of relapsingâ€“remitting multiple sclerosis: Results from a longitudinal study. Journal of the Neurological Sciences, 2014, 337, 180-185.	0.6	9
219	Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurology, 2015, 15, 252.	1.8	9
220	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. PLoS ONE, 2018, 13, e0200532.	2.5	9
221	Examining the validity of the multiple-sclerosis walking scale-12 with Rasch analysis: Results from an Italian study. Multiple Sclerosis and Related Disorders, 2019, 36, 101400.	2.1	9
222	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463.	3.3	9
223	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	4.7	9
224	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Multiple Sclerosis Journal, 2021, 27, 2284-2287.	3.3	9
225	Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. Multiple Sclerosis Journal, 2001, 7, 101-104.	3.3	8
226	Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 220-222.	2.1	8
227	Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1331-1340.	1.9	8
228	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Frontiers in Neurology, 2020, 11, 105.	2.5	8
229	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.6	8
230	Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis. Annals of Neurology, 2022, 91, 483-495.	5.8	8
231	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. Journal of Clinical Medicine, 2022, 11, 942.	2.5	8
232	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.1	8
233	Signs and symptoms of COVIDâ€19 in patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 3728-3736.	3.6	8
234	US health insurance is an obstacle to disease-modifying treatments in MS. Neurology, 2016, 87, 346-347.	1.1	7

#	Article	IF	Citations
235	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Neurological Sciences, 2016, 37, 437-442.	2.0	7
236	A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2017, 6, 161-173.	3.5	7
237	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. European Journal of Neurology, 2019, 26, e90-e91.	3.6	7
238	Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 875-883.	3.3	7
239	Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY). Neurotherapeutics, 2023, 20, 1696-1706.	4.7	7
240	Cognitive impairment and â€œinvisible symptomsâ€•are not associated with CCSVI in MS. BMC Neurology, 2013, 13, 97.	1.8	6
241	Is the basic trunk control recovery different between stroke patients with right and left hemiparesis?. NeuroRehabilitation, 2014, 35, 215-220.	1.3	6
242	Extensive bilateral striopallidodentate calcinosis: a 50Âyears history of hypoparathyroidism presenting like a parkinsonian syndrome. Journal of Neurology, 2016, 263, 1876-1879.	3.8	6
243	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	2.1	6
244	Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance ManagerÂ® evaluation study. Multiple Sclerosis and Related Disorders, 2018, 26, 46-51.	2.1	6
245	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423.	0.6	6
246	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. Neurology, 2021, 96, e214-e227.	1.1	6
247	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. Frontiers in Neurology, 2020, 11, 756.	2.5	6
248	Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. International Journal of Rehabilitation Research, 2020, 43, 199-205.	1.4	6
249	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation, 2020, 40, 319-326.	2.2	6
250	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Review of Neurotherapeutics, 2020, 20, 771-782.	2.8	6
251	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	2.0	6
252	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. CNS Drugs, 2020, 34, 535-543.	6.2	6

#	Article	IF	Citations
253	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	3.6	6
254	Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates. Journal of Psychiatry and Psychiatric Disorders, 2019, 03, .	0.0	6
255	Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. Multiple Sclerosis Journal, 2022, 28, 2243-2252.	3.3	6
256	Pharmacologic management of spasticity in multiple sclerosis. Neurological Sciences, 2006, 27, s310-s315.	2.0	5
257	Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Acta Neurologica Scandinavica, 2014, 130, e41-e44.	2.2	5
258	Multiple sclerosis and amyotrophic lateral sclerosis: a human leukocyte antigen challenge. Neurological Sciences, 2017, 38, 1501-1503.	2.0	5
259	Palliative care in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 123-127.	2.8	5
260	Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Review of Clinical Pharmacology, 2018, 11, 531-536.	3.2	5
261	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920.	6.0	5
262	BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT^{Â®} . Patient Preference and Adherence, 2020, Volume 14, 771-779.	1.9	5
263	Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. Journal of Neurology, 2020, 267, 1812-1823.	3.8	5
264	Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 5588.	2.7	5
265	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Journal of Neurology, 2022, 269, 1463-1469.	3.8	5
266	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	2.5	5
267	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurology, 2021, 21, 462.	1.8	5
268	Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. Current Neuropharmacology, 2022, 20, 1978-1987.	3.0	5
269	Correlation between patientâ€reported manual ability and three objective measures of upper limb function in people with multiple sclerosis. European Journal of Neurology, 2023, 30, 172-178.	3.6	5
270	The Antiinflammatory Cytokine Interleukin-13 is not Detectable in the Circulation of Multiple Sclerosis Patients and is not Inducible by Interferon-Î² 1b Treatment, that Neither Modifies its ex vivo Secretion from Peripheral Blood Mononuclear Cells. Autoimmunity, 2000, 32, 265-270.	2.6	4

#	Article	IF	Citations
271	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics, 2015, 15, 251-268.	2.8	4
272	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.3	4
273	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	3.8	4
274	Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. Multiple Sclerosis and Related Disorders, 2021, 49, 102756.	2.1	4
275	Reliability of televisits for patients with mild relapsingâ€“remitting multiple sclerosis in the COVID-19 era. Neurological Sciences, 2022, 43, 2253-2261.	2.0	4
276	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.3	4
277	Paediatric Multiple Sclerosis: A Scoping Review of Patientsâ€™ and Parentsâ€™ Perspectives. Children, 2022, 9, 11.	1.5	4
278	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103909.	2.1	4
279	Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Multiple Sclerosis Journal, 2023, 29, 1808-1818.	3.3	4
280	Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. Journal of Neurology, 1996, 243, 293-301.	3.8	3
281	Non-pharmacologic interventions for spasticity associated with multiple sclerosis. Neurological Sciences, 2006, 27, s316-s319.	2.0	3
282	Hormone replacement in menopausal women with multiple sclerosis. Neurology, 2016, 87, 1430-1431.	1.1	3
283	Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 327-327.	6.0	3
284	Lack of association between Toxocara canis and multiple sclerosis: A population-based caseâ€“control study. Multiple Sclerosis Journal, 2020, 26, 258-259.	3.3	3
285	Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders, 2021, 55, 103160.	2.1	3
286	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. Value in Health, 2022, 25, 1489-1498.	0.3	3
287	Pregnancy planning and management for women with multiple sclerosis: what has changed over the last 15 years? An Italian single-center experience. Multiple Sclerosis and Related Disorders, 2023, 70, 104526.	2.1	3
288	Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal, 2023, 29, 326-332.	3.3	3

#	Article	IF	Citations
289	Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression. Journal of Clinical Medicine, 2023, 12, 2215.	2.5	3
290	Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. ClinicoEconomics and Outcomes Research, 2009, 1, 45.	1.9	2
291	Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Review of Precision Medicine and Drug Development, 2016, 1, 353-360.	0.6	2
292	Lack of evidence for Toxocara infection in Italian myelitis patients. Neurological Sciences, 2020, 41, 239-241.	2.0	2
293	Palliative care in multiple sclerosis: European guideline. Multiple Sclerosis Journal, 2020, 26, 1009-1011.	3.3	2
294	Real world comparison of teriflunomide and dimethyl fumarate in naÃ¯ve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Multiple Sclerosis and Related Disorders, 2022, 58, 103489.	2.1	2
295	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. International Journal of Environmental Research and Public Health, 2022, 19, 6069.	2.7	2
296	Ataxia with vitamin E deficiency caused by a new compound heterozygous mutation. Neurological Sciences, 2016, 37, 1571-1572.	2.0	1
297	Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opinion on Pharmacotherapy, 2017, 18, 45-55.	1.9	1
298	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 341-352.	3.4	1
299	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. Autoimmunity Reviews, 2019, 18, 102365.	5.9	1
300	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.8	1
301	Newest Evidence for Tetrahydrocannabinol:Cannabidiol Oromucosal Spray From Postapproval Pragmatic Studies. Neurodegenerative Disease Management, 2019, 9, 3-7.	2.3	1
302	Reply to Comment on â€œEnvironmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Studyâ€• International Journal of Environmental Research and Public Health, 2020, 17, 6492.	2.7	1
303	Quality of Life in Patients Affected by Multiple Sclerosis: A Systematic Review. , 2010, , 3769-3783.		1
304	Spinal needle and post-dural puncture headache. Neurological Sciences, 2022, 43, 1467-1468.	2.0	1
305	Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology, 2023, 30, 1014-1024.	3.6	1
306	Sars-CoV2 infection in pregnant women with multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 1090-1098.	3.3	1

#	Article	IF	Citations
307	An Internet- and Kinect-Based Multiple Sclerosis Fitness Intervention Training With Pilates Exercises: Development and Usability Study. JMIR Serious Games, 0, 11, e41371.	3.3	1
308	A dynamic interpretation of ÎºFLC index for the diagnosis of multiple sclerosis: a change of perspective. Journal of Neurology, 0, , .	3.8	1
309	Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2023, 80, 105131.	2.1	1
310	Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60. Journal of Neurology, Neurosurgery and Psychiatry, 2024, 95, 767-774.	6.0	1
311	Corrigendum to â€œExpression of DNA methylation genes in secondary progressive multiple sclerosisâ€•[J. Neuroimmunol. 290 (2016 Jan. 15) 66â€“9]. Journal of Neuroimmunology, 2016, 295-296, 163.	2.4	0
312	The Cost-effectiveness of SativexÂ®: The Italian Experience Based on " in Resistant Multiple Sclerosis Spasticity: Discontinuation Study in a Large Population of Italian Patients, SA.FE. Study". International Journal of Neurorehabilitation, 2018, 05, .	0.1	0
313	Authorsâ€™ Response to the Letter to the Editor Regarding: A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2018, 7, 391-393.	3.5	0
314	An â€œall-wheel driveâ€•proposal to accelerate clinical research in common and rare neurological diseases. Neurological Sciences, 2020, 41, 789-793.	2.0	0
315	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889.	2.0	0
316	004â€…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. BMJ Neurology Open, 2021, , .	2.0	0
317	Aspetti che influenzano lâ€™adesione alla terapia. , 2013, , 81-87.		0
318	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î²1a in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 40, 101952.	2.1	0
319	Spasticity and Dystonia: A Brief Review. , 0, , .		0
320	Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study. Multiple Sclerosis and Related Disorders, 2023, 70, 104474.	2.1	0
321	A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols. Therapeutic Advances in Neurological Disorders, 2023, 16, .	3.8	0
322	Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of Medical Economics, 2024, 27, 109-125.	2.2	0
323	Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2024, 95, 620-625.	6.0	0
324	Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Therapeutic Advances in Neurological Disorders, 2024, 17, .	3.8	0

#	Article	IF	Citations
325	Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis. Neurology, 2024, 102, .	1.1	0
326	Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 0, , jnnp-2023-333307.	6.0	0
327	Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study. Neurotherapeutics, 2024, , e00363.	4.7	0
328	Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2024, 10, .	1.1	0
329	Early reduction of retinal thickness predicts physical and cognitive disability in newly diagnosed multiple sclerosis patients: results from a cross-sectional study. Neurological Sciences, 0, , .	2.0	0
330	Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA). Journal of Neurology, 0, , .	3.8	0
331	Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. Multiple Sclerosis Journal, 0, , .	3.3	0